Reference Detail

Ref Type
PMID
Authors Michael Wahl, Susan Chang, Joanna Phillips, Joseph Costello, Tali Mazor, Annette Molinaro, Janine Lupo, Sarah Nelson, Mitchel S. Berger, Michael Prados, Nicholas Butowski, Jennie Taylor, Jennifer Clarke, and Daphne Haas-Koganhttp://neuro-oncology.oxfordjo
Title A PROSPECTIVE PHASE II STUDY OF EVEROLIMUS FOR RECURRENT ADULT LOW GRADE GLIOMAS
Journal Neuro Oncol
Vol
Issue
Date
URL http://neuro-oncology.oxfordjournals.org/content/18/suppl_6/vi8.4.abstract?sid=d8ee130e-a72b-4041-8e4b-de5e91956109
Abstract Text Neuro Oncol (2016) 18 (suppl 6): vi8-vi9.

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Therapy Description
Drug Name Trade Name Synonyms Drug Classes Drug Description
Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown malignant glioma not applicable Everolimus Phase II Actionable In a Phase II trial, Afinitor (everolimus) treatment resulted in a 6-month progression free survival rate of 87% and 55% in patients with WHO grade II and III/IV glioma, respectively (Neuro Oncol (2016) 18 (suppl 6): vi8-vi9.). detail...